Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03182725 | Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome | PHASE3 | COMPLETED | 37 | — | — | Feb 6, 2018 | May 8, 2020 | Jun 29, 2021 | 1 | United States |
Orthostatic heart rate monitoring will be used to gauge heart rate changes.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Patient will consume one placebo pill twice a day for one month. |
| Ivabradine | EXPERIMENTAL | Patient will consume one dose of Ivabradine twice a day for one month. |
| Name | Type | Description |
|---|---|---|
| Ivabradine | DRUG | Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node. |
| Placebo | DRUG | A substance that has no therapeutic effect and will act as a control. |
Inclusion Criteria: * Subjects aged 18-65. * Subjects must have POTS diagnosis (Hyperadrenergic Subtype with NE\> 600pg/ml)) * Subjects with no structural heart disease * Subject with no arrhythmias * Subjects with norepinephrine levels greater than 600 pg/ml * Subjects with normal CBC, Metabolic, ...